Immunotherapy Study for Patients With Stage IV Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Metastatic Melanoma
Related studies linked through entity extraction aliases.
Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study
- Status
- COMPLETED
- Phase
- PHASE2
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
- Status
- TERMINATED
- Phase
- PHASE2
TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
- Status
- TERMINATED
- Phase
- PHASE2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
- Status
- TERMINATED
- Phase
- PHASE1
Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
The Jules Bordet Institute Molecular Profiling Program Feasibility Trial
- Status
- COMPLETED
- Phase
- NA
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
- Status
- UNKNOWN
- Phase
- N/A
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
- Status
- COMPLETED
- Phase
- PHASE1
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
- Status
- UNKNOWN
- Phase
- N/A
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
- Status
- TERMINATED
- Phase
- PHASE1
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2